M1 Kliniken AG
- WKN: A0STSQ
- ISIN: DE000A0STSQ8
- Land: Deutschland
Nachricht vom 04.10.2017 | 08:46
M1 Kliniken AG: M1 Kliniken AG decides to carry out a cash capital increase using the authorized capital with exclusion of subscription rights in the amount of up to 10% of the share capital to finance further growth investments.
M1 Kliniken AG / Key word(s): Capital Increase
M1 Kliniken AG decides to carry out a cash capital increase using the authorized capital with exclusion of subscription rights in the amount of up to 10% of the share capital to finance further growth investments.
The share capital of the company is to be increased by the partial utilization of the authorized capital 2015 of currently EUR 15,000,000.00 by issuing up to 1,500,000 bearer shares to a total of up to EUR 16,500,000.00. The new shares are to be eligible for dividends as of January 1,2017 and are to be offered to institutional investors by means of a placement procedure in accordance with the exemption provisions for private placements without a prospectus and included in the existing listing of the company's shares. The placement price will not be significantly lower than the market price.
The final placement volume and the placement price will be determined by the Management Board, with the approval of the Supervisory Board, after the placement procedure has been completed and announced in a separate ad hoc announcement.
M1 Kliniken AG intends to use the proceeds from the capital increase to finance further growth investments and, in particular, to finance the opening of additional M1 Med-Beauty locations.
M1 Kliniken AG
This document does not constitute an offer to sell or a solicitation of an offer to purchase any securities.
In particular, this document does not constitute an offer to purchase securities in the United States of America. Securities may not be sold or sold in the United States of America without prior registration under the U. S. Securities may not be sold or sold in the United States of America without prior registration. Securities Act of 1933, as amended or without prior registration, are sold or offered for sale only on the basis of a derogation. The shares of M1 Kliniken AG are not and will not be sold in accordance with the regulations of the U. S. Securities Act of 1933, as amended, and will not be offered or sold in the United States of America.
In the member states of the European Economic Area that have implemented the Prospectus Directive, this document is addressed exclusively to "qualified investors" within the meaning of the Prospectus Directive 2003/71/EC (including all amendments, in particular to Directive 2010/73/EC) together with all relevant implementing measures in the relevant member states.
Patrick Brenske, Management Board
|Company:||M1 Kliniken AG|
|Grünauer Straße 5|
|Phone:||+49 (0)30 / 88 70 862-25|
|Fax:||+49 (0)30 / 88 70 862-28|
|Listed:||Regulated Unofficial Market in Dusseldorf, Stuttgart; Open Market (Basic Board) in Frankfurt|
|End of Announcement||DGAP News Service|
M1 Kliniken AG starts international expansion: ...
M1 Kliniken AG opens further specialist centre ...
M1 Kliniken AG: M1 Kliniken AG successfully co ...
M1 Kliniken AG: M1 Kliniken AG decides to impl ...
On growth path with top-class medicine: M1 Kli ...
Der AKTIONÄR News
16. Januar 17:01 800%-Strategie: Union Pacific unter Volldampf
16. Januar 17:00 DAX trotzt dem Brexit-GAU - Kaufsignal in Schlagdistanz
16. Januar 16:48 Okta – Cybersecurity-Spezialist liefert satte Kursgewinne
News im Fokus
Deutsche Post AG: Deutsche Post AG nimmt Stellung zur beabsichtigten Entscheidung zur Preisregulierung
15. Januar 2019, 13:37
Original-Research: aventron AG (von First Berlin Equity Research GmbH): Buy aventron AG
16. Januar 2019